In 2019, powerful single-cell analyses were applied to liver cancer biology at an unprecedented level. In parallel with this achievement was the identification of serum α-fetoprotein as a biomarker for patient selection in the use of ramucirumab for liver cancer and that β-catenin activation can distinguish between liver cancer immunotherapy responders and non-responders.

中文翻译：

---

齐心协力，更好地治疗肝癌。

在2019年，功能强大的单细胞分析以前所未有的水平应用于肝癌生物学。与该成就同时进行的是鉴定血清α-甲胎蛋白作为雷莫昔单抗治疗肝癌的患者选择的生物标志物，并且β-catenin的激活可以区分肝癌免疫治疗反应者和非反应者。